Hydroxyzine Pamoate Dosing for Sleep
Hydroxyzine pamoate should NOT be used as a first-line treatment for insomnia, but when prescribed off-label for sleep, the typical dose is 25-50 mg at bedtime, with elderly patients starting at 25 mg.
Evidence-Based Recommendations
Guideline Position on Hydroxyzine
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines 1 do not recommend hydroxyzine for insomnia treatment. The guidelines specifically recommend against antihistamines like diphenhydramine (50 mg doses) for sleep onset or maintenance insomnia, and hydroxyzine falls into this same antihistamine class. The American College of Physicians guidelines 2 similarly found insufficient evidence for antihistamines in treating insomnia disorder.
FDA-Approved Dosing Information
The FDA label 3 provides hydroxyzine pamoate capsules in 25 mg, 50 mg, and 100 mg strengths. However, the FDA has not approved hydroxyzine for insomnia—its approved indications are for anxiety and pruritus. The label emphasizes:
- Elderly patients should start at low doses and be observed closely due to increased risk of confusion and over-sedation 3
- Drowsiness may occur, requiring caution with driving and operating machinery 3
- Potentiating effects occur with other CNS depressants, requiring dose reduction of concomitant medications 3
Clinical Research Evidence
When hydroxyzine has been studied for sleep (off-label use):
25 mg at bedtime showed efficacy in a randomized controlled trial of cirrhotic patients with minimal hepatic encephalopathy, improving both subjective sleep and objective actigraphy measures 4. However, one patient developed acute encephalopathy requiring drug cessation, highlighting safety concerns.
A 2023 systematic review 5 identified only 5 studies (207 total patients) evaluating hydroxyzine 25-100 mg at bedtime, showing mixed efficacy across sleep onset, maintenance, and quality measures. The review concluded hydroxyzine could be considered only as a short-term option when previous therapies failed, were not tolerated, or contraindicated.
In elderly subjects, a single 25 mg dose preserved memory and attention better than lorazepam 6, and pharmacokinetic studies showed prolonged half-life (29.3 hours) and large volume of distribution in the elderly 7, suggesting once-daily dosing is sufficient but accumulation risk exists.
Practical Dosing Algorithm
If hydroxyzine must be used for sleep (after FDA-approved options have been considered):
For Adults (18-64 years):
- Start: 25 mg at bedtime
- May increase to 50 mg at bedtime if inadequate response after 3-5 days
- Maximum: 100 mg at bedtime (though evidence is limited at this dose)
- Duration: Short-term only (days to weeks, not months)
For Elderly (≥65 years):
- Start: 25 mg at bedtime 3
- Do not increase without careful monitoring for confusion, over-sedation, falls
- Consider even lower starting doses (12.5 mg) given prolonged half-life 7
- Enhanced caution with renal impairment (extent of renal excretion undetermined) 3
Critical Safety Considerations
⚠️ Common Pitfalls:
Anticholinergic burden: Dry mouth is the most common side effect 5, but elderly patients face increased risks of cognitive impairment, urinary retention, and constipation
Drug interactions: Reduce doses of concurrent CNS depressants (opioids, benzodiazepines, alcohol) 3
Next-day sedation: The 29-hour half-life in elderly 7 means significant daytime carryover effects
Lack of long-term data: No studies establish safety or efficacy beyond short-term use 5
Risk in liver disease: One case of precipitated hepatic encephalopathy occurred at 25 mg 4
Preferred Alternatives
Before considering hydroxyzine, the AASM guidelines 1 recommend:
- First-line: Cognitive behavioral therapy for insomnia (CBT-I)
- Pharmacologic options with evidence:
- Eszopiclone 2-3 mg
- Zolpidem 10 mg (5 mg in elderly)
- Suvorexant 10-20 mg
- Doxepin 3-6 mg (for sleep maintenance)
- Ramelteon 8 mg (for sleep onset)
These agents have demonstrated benefits outweighing harms in systematic reviews, unlike hydroxyzine which lacks robust evidence 2, 1.